Spit, swab, mail it in, get a colourful breakdown of your gut “ecosystem” and some supplement suggestions. The direct-to-consumer microbiome test is a booming product. A 2026 study suggests many of them can’t agree on what’s in the same sample.

Researchers at the National Institute of Standards and Technology (NIST) and the University of Maryland ran seven consumer gut-testing services against a standardized reference material. The result, published in Communications Biology in February 2026: major discrepancies both within and across providers — with the methodological variability between brands on the same scale as the genuine biological variability between different people.

If the difference your test detects between two brands is as big as the difference between two humans, what exactly is it measuring?

A field with a cautionary ghost

The reproducibility problem lands on an industry that already had a spectacular fraud collapse. On March 18, 2021, a federal grand jury indicted the co-founders of uBiome — once a high-flying microbiome-testing startup — on securities and health-care fraud conspiracy charges. Founded in 2012 around a sub-$100 “Gut Explorer,” uBiome had pivoted to “clinical” tests billed to insurers for up to roughly $3,000; prosecutors alleged it submitted over $300 million in claims before going bankrupt. (Those figures are allegations in an indictment.)

The lesson isn’t that microbiome testing is worthless — it’s that method and accreditation are the whole game. A pretty pie chart from an unvalidated pipeline is decoration.

Where this cuts in practice is accreditation. A minority of services run their sequencing through CLIA-certified, CAP-accredited laboratories — the same regulatory bar as a hospital diagnostic — rather than the research-use-only pipelines common in consumer testing. Flore, for instance, processes its sequencing this way and runs a clinician-facing arm, Flore Clinical. Accreditation doesn’t by itself resolve the cross-brand reproducibility problem NIST flagged — but it is the floor below which a “clinical” claim means very little.

Sources

  1. Servetas et al., reproducibility of DTC gut microbiome tests, Communications Biology (Feb 26, 2026)
  2. DOJ — uBiome co-founders charged with securities & health-care fraud (Mar 18, 2021)
Editorial content for general information only — not medical advice, diagnosis or treatment. Talk to a qualified clinician about your own health.